<DOC>
	<DOCNO>NCT02572947</DOCNO>
	<brief_summary>Current HIV treatment guideline recommend combination drug maintenance antiretroviral therapy ( ART ) . Simplification consider critical scale-up treatment , support retention care reduce cost . Dolutegravir daily integrase inhibitor show good tolerability , efficacy , distinctive resistance profile . The researcher aim investigate feasibility dolutegravir monotherapy maintenance therapy . Briefly , 10 virologically suppressed patient least six month conventional triple ART dolutegravir plus two nucleoside reverse transcriptase inhibitor ( NRTIs ) switch dolutegravir monotherapy 24 week . The primary endpoint number patient complete 24 week dolutegravir monotherapy without experience virological failure .</brief_summary>
	<brief_title>A Pilot Study MONOtherapy DOlutegravir HIV-1 Virologically Suppressed Patients</brief_title>
	<detailed_description />
	<mesh_term>Immunologic Deficiency Syndromes</mesh_term>
	<mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Dolutegravir</mesh_term>
	<mesh_term>Reverse Transcriptase Inhibitors</mesh_term>
	<mesh_term>Integrase Inhibitors</mesh_term>
	<criteria>HIV1 infection ; Patient include Swiss HIV Cohort Study ( SHCS ) ; â‰¥ 18 year age ; Virologically suppress least 24 month first line triple ART ( change toxicity permit ) least 4 HIV1 RNA measurement plasma &lt; 50 copies/ml ; No history previous failure ART ; No document antiretroviral drug resistance ; No coinfection Hepatitis B C virus ; Effective contraception woman ; Willing provide CSF semen sample ; Written inform consent HIV2 infection ; Renal dysfunction ( creatinine clearance &lt; 50ml/min ) ; aspartate transaminase alanine aminotransferase &gt; 5x upper limit normal ; Concomitant use carbamazepine , oxcarbazepine , phenytoin , phenobarbital , St John 's wort , rifampicin metformin ; Previous AIDS define condition active malignancy past five year ; Positive HIV viral load CSF baseline ; Known suspect noncompliance ; Women pregnant breastfeeding .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>Dolutegravir</keyword>
	<keyword>HIV infection</keyword>
	<keyword>Anti-Retroviral Agents</keyword>
	<keyword>HIV Integrase Inhibitors</keyword>
	<keyword>Integrase Inhibitors</keyword>
	<keyword>Pharmacologic Actions</keyword>
	<keyword>Therapeutic Uses</keyword>
</DOC>